Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic
Autor: | Covadonga Marti, J.I. Sánchez-Méndez |
---|---|
Přispěvatelé: | UAM. Departamento de Obstetricia y Ginecología |
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Cancer Research medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Medicina Short Communication Primary care 03 medical and health sciences 0302 clinical medicine Breast cancer breast cancer Pandemic Epidemiology medicine Endocrine system Intensive care medicine luminal business.industry endocrine therapy neoadjuvant Endocrine therapy Attendance COVID-19 medicine.disease 030104 developmental biology Oncology 030220 oncology & carcinogenesis business |
Zdroj: | Biblos-e Archivo. Repositorio Institucional de la UAM instname ecancermedicalscience |
Popis: | The epidemiological emergency caused by CoV-2 (COVID-19) has changed priorities in breast cancer management. In those places where the pandemic has had the greatest effect, it is of paramount importance for most patients to be at home, reducing or postponing their attendance at clinics, as well as avoiding surgeries. In this scenario, neoadjuvant endocrine treatment could be an appropriate alternative treatment for hormone receptor positive breast cancer (luminal-like tumours) in order to minimise hospital admissions and to delay elective surgeries. Accordingly, we present a simple protocol that can be applied to most cases of luminal-like breast cancer and is appropriate for the majority of secondary or tertiary medical centres, or even primary care. |
Databáze: | OpenAIRE |
Externí odkaz: |